Patent intelligence · US
US 12110344
Antibodies that bind to cis and uses thereof
Antibodies that bind to cis and uses thereof
Patent details — US 12110344
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 8, 2024
- Expiration
- Oct 3, 2044
- Applicant
- DIANTHUS THERAPEUTICS OPCO, INC.
- Claims
- 25
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545
Quick answer
US 12110344 (Antibodies that bind to cis and uses thereof) is held by DIANTHUS THERAPEUTICS OPCO, INC.. Status: granted. Granted Oct 8, 2024. Expires Oct 3, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- DIANTHUS THERAPEUTICS OPCO, INC.
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K39/00, A61P
More from DIANTHUS THERAPEUTICS OPCO, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12110344?
US 12110344 (Antibodies that bind to cis and uses thereof) is held by DIANTHUS THERAPEUTICS OPCO, INC.. Status: granted. Granted Oct 8, 2024. Expires Oct 3, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12110344?
DIANTHUS THERAPEUTICS OPCO, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 12110344 expire?
Our index shows an expiration date of Oct 3, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.